Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences Inc. is focused on advancing innovative therapeutic solutions for hepatitis B virus (HBV) infection, aiming to significantly enhance cure rates through multiple drug candidates that target various stages of the HBV lifecycle. The promising data from their HBV-cure program, including strong antiviral activity and favorable safety profiles for leading candidates such as ABI-5366, indicates a solid foundation for future success and potential revenue generation, with a peak sales estimate of nearly $4 billion in the U.S. Additionally, the recent $175 million equity financing reinforces the company's financial health and positions it well to sustain operations through 2027 while continuing to optimize its clinical programs.

Bears say

Assembly Biosciences Inc. faces significant challenges as it seeks to advance its clinical-stage biotechnology programs, particularly in the treatment of hepatitis B virus (HBV) infection, which is primarily responsible for its revenue generation. The company's reliance on the HBV-cure program is undermined by potential negative outcomes for its drug candidates ABI-6250 and ABI-1179/5366, leading to concerns about their viability and the ability to progress in clinical trials. Additionally, Assembly has not yet demonstrated profitability, and its historical financial losses raise red flags regarding the sustainability of its operations and ability to effectively support its therapeutic development initiatives.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.